摘要
目的观察双嘧达莫联合厄贝沙坦对Ig A肾病的疗效及其安全性。方法将Ig A肾病患者62例随机分为治疗组32例和对照组30例,治疗组给予双嘧达莫150 mg/d、厄贝沙坦150 mg^300 mg/d,共12周;对照组单纯给予双嘧达莫150mg/d,共12周。观察两组患者治疗前后收缩压(SBP)、舒张压(DBP)、24 h尿蛋白定量、血尿素氮(BUN)、肌酐(Cr)和血K+等变化。结果治疗12周后,治疗组患者SBP、DBP、24 h尿蛋白定量、BUN、Cr均降低,治疗效果明显(P<0.05);对照组患者用药后SBP、DBP、24 h尿蛋白定量、BUN、Cr均无明显降低,治疗效果不明显(P>0.05)。结论双嘧达莫联合厄贝沙坦治疗Ig A肾病能明显降低血压、减少尿蛋白、改善肾功能,且无明显不良反应。
Objective To investigate the effectiveness and the safety of dipyridamole and irbesartan on Ig A nephropathy.Methods 62 cases of Ig A nephropathy were randomly divided into treatment group and control group. Patients of the treatment group（n = 32） were given 150 mg dipyridamole and 150 ~ 300 mg irbesartan once a day for 12 weeks and patients of the control group（n = 30） were only given 150 mg dipyridamole. Systolic blood pressure,diastolic blood pressure,proteinuria in 24 hours,blood urea nitrogen,creatinine and potassium were observed. Results Systolic blood pressure, diastolic blood pressure,proteinuria in 24 hours,blood urea nitrogen and creatinine in treatment group decreased significantly（P〉0.05）. There was no decrease（P〈0.05） in control group after treatment. Conclusion Dipyridamole and Irbesartan can significantly lower blood pressure and proteinuria and improve renal function without severe side-effects in treating Ig A nephropathy.
出处
《中华保健医学杂志》
2014年第5期347-348,共2页
Chinese Journal of Health Care and Medicine
